This application requests renewal for years 29-33 of the NCI Cancer Center Support Grant (CCSG) for the Barbara Ann Karmanos Cancer Institute (KCI) at Wayne State University. The Programs of KCI reflect the cancer needs of the greater Metropolitan Detroit area. This is an industrialized, urban and ethnically diverse community with a disproportionate number of medically disadvantaged, low socio-economic citizens. KCI has a long-standing and extensive commitment to both research and clinical services that address the prevention, early detection and treatment of cancer, particularly of African Americans who carry a disproportionate cancer burden. This application requests support for five Programs, ten Cores, Developmental Funds, five Staff Investigators, and related administrative support. KCI's established Programs are Breast Cancer Biology;Developmental Therapeutics;Molecular Biology and Genetics;Population Studies and Disparities Research, and Proteases and Cancer. Our Programs are organized to integrate basic, translational, and clinical research with population research-based cancer control activities. Additionally, CCSG support is requested for ten Cores, in Behavioral and Field Research;Biorepository;Epidemiology Research;Genomics;Microscopy, Imaging and Cytometry Resources;Pharmacology;Proteomics;Systems and Computational Biology;Biostatistics;and Clinical Trials Office. KCI fosters inter-disciplinary interactions and collaborations, utilizes CCSG Developmental Funds to recruit new investigators, encourages translational research Programs, and develops new Shared Resources (Cores) to support KCI members. Research growth continues, as demonstrated by increases in the number of publications and the recruitment of internationally recognized scientists. KCI has 235 members, 170 are Scientific Members and 65 are Clinical Members representing 40 departments and institutes from Wayne State University, Henry Ford Health System, University of Windsor, and Michigan State University. KCI's total annual direct grant funding is $63,296,703 of which $42,441,739 is peer reviewed funding. Of the peer reviewed funding, 6 1 % is from NCI. Over the last grant period, members'published 2,980 papers, 38% and 35% were intra- and inter-programmatic, respectively and 24% were both intra- and inter-programmatic.

Public Health Relevance

Cancer is the second leading cause of mortality in the United States and disproportionately affects minorities. It is through the clinical, basic, population and translational research conducted at KCI that we can make strides towards reducing mortality and morbidity associated with cancer, with a continued commitment to address the disproportionate cancer burden among minorities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA022453-30S2
Application #
8532387
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-08-08
Project End
2015-11-30
Budget Start
2012-09-13
Budget End
2013-11-30
Support Year
30
Fiscal Year
2012
Total Cost
$75,000
Indirect Cost
$25,658
Name
Wayne State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963
An, Mingrui; Wu, Jing; Zhu, Jianhui et al. (2018) Comparison of an Optimized Ultracentrifugation Method versus Size-Exclusion Chromatography for Isolation of Exosomes from Human Serum. J Proteome Res 17:3599-3605
Yu, Chunsong; An, Myunggi; Jones, Evan et al. (2018) Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity. Pharm Res 35:56
Kariburyo, Furaha; Wang, Yuexi; Cheng, I-Ning Elaine et al. (2018) Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study. BMC Urol 18:55
Thakur, Manish K; Heilbrun, Lance; Dobson, Kimberlee et al. (2018) Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer 16:e695-e703
Feldmann, Daniel P; Cheng, Yilong; Kandil, Rima et al. (2018) In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells. J Control Release 276:50-58
Vaishampayan, Ulka (2018) Advantages and Adversities of the Weighted Toxicity Score. Clin Cancer Res 24:4918-4920
Wang, Zhaoxian; Sau, Samaresh; Alsaab, Hashem O et al. (2018) CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer. Nanomedicine 14:1441-1454
Ravindra, Manasa; Wilson, Mike R; Tong, Nian et al. (2018) Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor ? and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis. J Med Chem 61:4228-4248
Kim, Seongho; Wong, Weng Kee (2018) Extended two-stage adaptive designs with three target responses for phase II clinical trials. Stat Methods Med Res 27:3628-3642

Showing the most recent 10 out of 826 publications